Phio Pharmaceuticals
PHIO
2 hedge funds and large institutions have $6.95M invested in Phio Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$6.35M |
| 2 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$3.18M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BC
1
Broadfin Capital
New York
| $4.81M | +$6.35M | +2 | New |
|
|
NI
2
Numeric Investors
Boston,
Massachusetts
| $1.4M | +$3.18M | +1 | New |
|
3
Jane Street
New York
| $165K | – | – | – |
|
4
Geode Capital Management
Boston,
Massachusetts
| $107K | – | – | – |
|
|
SIM
5
Spark Investment Management
New York
| $107K | – | – | – |
|
|
TCM
6
Tang Capital Management
San Diego,
California
| $78K | – | – | – |
|
7
Morgan Stanley
New York
| $72K | – | – | – |
|
8
Northern Trust
Chicago,
Illinois
| $66K | – | – | – |
|
9
Citadel Advisors
Miami,
Florida
| $53K | – | – | – |
|
10
Goldman Sachs
New York
| $45K | – | – | – |
|
|
U
11
UBS
Zurich,
Switzerland
| $21K | – | – | – |
|
|
TRCT
12
Tower Research Capital (TRC)
New York
| $18K | – | – | – |
|
13
Barclays
London,
United Kingdom
| $4K | – | – | – |
|
|
LTFS
14
Ladenburg Thalmann Financial Services
Miami,
Florida
| $2K | – | – | – |
|
15
Citigroup
New York
| $1K | – | – | – |
|
|
AIG
16
American International Group
New York
| $47 | – | – | – |
|
PHIO Hedge Fund Activity: Q1 2014 in Review
2 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q1 2014, worth a combined $6.95M.
Buyers outnumbered sellers: 2 funds opened new PHIO positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Broadfin Capital, opening a new position worth an estimated $6.35M.
- 2 institutional investors held Phio Pharmaceuticals (PHIO) as of Q1 2014, up from 0 in Q4 2013.
- Funds reported $6.95M of Phio Pharmaceuticals stock for Q1 2014.
- 2 funds opened new Phio Pharmaceuticals positions in Q1 2014 and 0 closed out, a net change of +2 holders.
- The largest Phio Pharmaceuticals buyer in Q1 2014 was Broadfin Capital, an estimated $6.35M added.
Based on aggregated 13F filings for Q1 2014.